AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug
AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.Trending
AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.| Symbol | Last Price | Change | % Change |
|---|---|---|---|
Asset manager Janus Henderson gets bought by Trian, General Catalyst for $7.4 billion
Three top Wall Street analysts stay bullish on Nvidia stock. Here’s why
Your CEO wants to be a social media influencer. Is it cool or cringy?
Activist Ananym Capital urges LKQ to sell its European auto parts business
Abel takes over for Buffett in less than two weeks. Wall Street has some advice for new Berkshire CEO
Friday could be a wild day of trading on Wall Street. Here’s why
Baron Capital rolls out five active ETFs, SpaceX becomes the firm’s biggest investment
Top Wall Street analysts are upbeat on these 3 dividend stocks for enhanced returns
Activist Starboard reveals 5% stake in Clearwater as tech company reviews its options
End of ‘The Berkshire Way’? Combs’ departure isn’t only big change as Buffett transition nears